An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1622-1627

  Witzig, T E ^a   Vose, J M ^b   Zinzani, P L ^c   Reeder, C B ^a   Buckstein, R ^d   Polikoff, J A ^e   Bouabdallah, R ^f   Haioun, C ^g   Tilly, H ^h   Guo, P ⁱ   Pietronigro, D ⁱ   Ervin Haynes, A L ⁱ   Czuczman, M S ^j  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e KAISER PERMANENTE MEDICAL CENTER   (United States)

^f Department of Hematology   (United States)

^g Department of Hôpital Henri Mondor AP HP ^*  (United States)

^h CENTRE HENRI BECQUEREL   (France)

ⁱ CELGENE CORPORATION   (United States)

^j ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

Large cell lymphoma; Lenalidomide; Mantle cell lymphoma

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; RITUXIMAB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; BACKACHE; BONE MARROW SUPPRESSION; CANCER PAIN; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; HYPOKALEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY PERIOD; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TRANSFORMED LYMPHOMA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79959722615     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq626     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin ncol 2006; 24: 3121-3127.
3. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 46: 235-242.
4. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma [see comments]. N Engl J Med 1995; 333: 1540-1545.
5. Herrmann A, Hoster E, Zwingers T et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511-518.
6. Geisler CH, Kolstad A, Laurell A et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687-2693.
7. Fisher RI, Bernstein SH, Kahl BS et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874.
8. Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-5356.
9. Ansell SM, Inwards DJ, Rowland KM Jr et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment roup. Cancer 2008; 113: 508-514.
10. Kouroukis CT, Belch A, Crump M et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical rials Group. J Clin Oncol 2003; 21: 1740-1745.
11. Al-Tourah AJ, Gill KK, Chhanabhai M et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 5165-5169.
12. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through K cell activation. Cancer Immunol Immunother 2008; 57: 1849-1859.
13. Wu L, Adams M, Carter T et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008; 14: 4650-4657.
14. Gorgun G, Ramsay AG, Holderried TA et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. roc Natl Acad Sci USA 2009; 106: 6250-6255.
15. Gaidarova S, Corral LG, Gleizer E et al. Lenalidomide enhances anti-tumor effect of {gamma}{delta} T Cells against mantle cell lymphoma. Blood 2008; 112: 2616 (ASH Annual eeting Abstracts).
16. Gandhi AK, Kang J, Naziruddin S et al. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex ssembly. Leuk Res 2006; 30: 849-858.
17. Verhelle D, Corral LG, Wong K et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 7: 746-755.
18. Witzig TE, Wiernik PH, Moore T et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 009; 27: 5404-5409.
19. Wiernik PH, Lossos IS, Tuscano JM et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952-4957.
20. Habermann TM, Lossos IS, Justice G et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J aematol 2009; 145: 344-349.
21. Cheson B, Horning S, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244-1253.
22. Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle ell lymphoma. J Clin Oncol 2009; 27: 3822-3829.
23. Witzig TE, Habermann TM, Reeder C et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed non-Hodgkin's lymphoma and Hodgkin disease. Haematologia 009; 94 (Suppl 2): 436 (Abstr 1081).
24. Goy A, Younes A, McLaughlin P et al. Phase II Study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667-675.
25. Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximabrefractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, ingle-agent study. J Clin Oncol 2008; 26: 204-210.
26. Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259-1266.
27. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin ncol 2002; 20: 3262-3269.
28. Smith SM, Pro B, Cisneros A et al. Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes. J Clin Oncol 2008; 26: (Abstr 8514).
29. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter hase II study. Blood 1998; 92: 1927-1932.
30. Rothe A, Schulz H, Elter T et al. Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma. Haematologica 2004; 89: 875-876.
31. Tobinai K, Igarashi T, Itoh K et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 2004; 15: 821-830.
32. Fossa A, Santoro A, Hiddemann W et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 786-3792.